102 related articles for article (PubMed ID: 20453636)
1. Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy.
Opstad TB; Eilertsen AL; Høibraaten E; Skretting G; Sandset PM
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):516-21. PubMed ID: 20453636
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden.
Lincz LF; Adams MJ; Scorgie FE; Thom J; Baker RI; Seldon M
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):559-64. PubMed ID: 17762532
[TBL] [Abstract][Full Text] [Related]
3. Analysis of a T-287C polymorphism in the tissue factor pathway inhibitor gene and identification of a repressor element in the promoter.
Amini Nekoo A; Iles D
Thromb Res; 2008; 121(6):813-9. PubMed ID: 17931693
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of polymorphisms in the human TFPI gene.
Skretting G; Stavik B; Landvik NE; Myklebust CF; Iversen N; Zienolddiny S; Sandset PM
Biochem Biophys Res Commun; 2010 Jun; 397(1):106-11. PubMed ID: 20519147
[TBL] [Abstract][Full Text] [Related]
5. The -33T-->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations.
Ameziane N; Seguin C; Borgel D; Fumeron F; Moatti D; Alhenc-Gelas M; Grandchamp B; Aiach M; Emmerich J; de Prost D
Thromb Haemost; 2002 Aug; 88(2):195-9. PubMed ID: 12195688
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in antithrombin and in tissue factor pathway inhibitor genes are associated with recurrent pregnancy loss.
Guerra-Shinohara EM; Bertinato JF; Tosin Bueno C; Cordeiro da Silva K; Burlacchini de Carvalho MH; Pulcineli Vieira Francisco R; Zugaib M; Cerda A; Morelli VM
Thromb Haemost; 2012 Oct; 108(4):693-700. PubMed ID: 22918506
[TBL] [Abstract][Full Text] [Related]
7. Association of Asn221Ser mutation in tissue factor pathway inhibitor-beta with plasma total tissue factor pathway inhibitor level.
Ishikawa J; Okada H; Kato H; Takeshita S; Honda S; Kawasaki T; Suehisa E; Tsuji H; Madoiwa S; Sakata Y; Kojima T; Murata M; Ikeda Y; Kokubo Y; Okamura T; Tomoike H; Miyata T
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):22-6. PubMed ID: 20523161
[TBL] [Abstract][Full Text] [Related]
8. The 536C-->T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis.
Kleesiek K; Schmidt M; Götting C; Schwenz B; Lange S; Müller-Berghaus G; Brinkmann T; Prohaska W
Thromb Haemost; 1999 Jul; 82(1):1-5. PubMed ID: 10456444
[TBL] [Abstract][Full Text] [Related]
9. Association of genetic polymorphisms with plasma TFPI level: Boon or curse for DVT patients - Study from India.
Kamal K; Amit S; Kanwaljeet S; Ravi R; Hareram P; Ravi K; Kumar KV; Pravas M; Renu S
Blood Cells Mol Dis; 2017 Jul; 66():31-36. PubMed ID: 28810169
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in the protein C gene as risk factor for venous thrombosis.
Pomp ER; Doggen CJ; Vos HL; Reitsma PH; Rosendaal FR
Thromb Haemost; 2009 Jan; 101(1):62-7. PubMed ID: 19132190
[TBL] [Abstract][Full Text] [Related]
11. A new T-287C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels.
Moatti D; Haidar B; Fumeron F; Gauci L; Boudvillain O; Seknadji P; Olliver V; Aumont MC; de Prost D
Thromb Haemost; 2000 Aug; 84(2):244-9. PubMed ID: 10959696
[TBL] [Abstract][Full Text] [Related]
12. [Association of single nucleotide polymorphisms of tissue factor and tissue factor pathway inhibitor with venous thromboembolism in patients with lung cancer].
Zhang XL; Zhu J; Chen WH; Zhai ZG; Zhang YH
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(12):901-906. PubMed ID: 29665662
[No Abstract] [Full Text] [Related]
13. A locus on chromosome 2 influences levels of tissue factor pathway inhibitor: results from the GAIT study.
Almasy L; Soria JM; Souto JC; Warren DM; Buil A; Borrell M; Muñoz X; Sala N; Lathrop M; Fontcuberta J; Blangero J
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1489-92. PubMed ID: 15845911
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis.
Sidelmann JJ; Bladbjerg EM; Gram J; Münster AM; Jespersen J
Blood Coagul Fibrinolysis; 2008 Jul; 19(5):405-9. PubMed ID: 18600090
[TBL] [Abstract][Full Text] [Related]
15. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
[TBL] [Abstract][Full Text] [Related]
16. Catechol-O-methyltransferase genotype is associated with plasma total homocysteine levels and may increase venous thrombosis risk.
Gellekink H; Muntjewerff JW; Vermeulen SH; Hermus AR; Blom HJ; den Heijer M
Thromb Haemost; 2007 Dec; 98(6):1226-31. PubMed ID: 18064318
[TBL] [Abstract][Full Text] [Related]
17. Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis.
Aléssio AM; Höehr NF; Siqueira LH; Ozelo MC; de Pádua Mansur A; Annichino-Bizzacchi JM
Thromb Res; 2007; 120(5):639-45. PubMed ID: 17184825
[TBL] [Abstract][Full Text] [Related]
18. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study.
Bladbjerg EM; Madsen JS; Kristensen SR; Abrahamsen B; Brixen K; Mosekilde L; Jespersen J
J Thromb Haemost; 2003 Jun; 1(6):1208-14. PubMed ID: 12871321
[TBL] [Abstract][Full Text] [Related]
19. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population.
Hoppe B; Tolou F; Dörner T; Kiesewetter H; Salama A
Thromb Haemost; 2006 Oct; 96(4):465-70. PubMed ID: 17003923
[TBL] [Abstract][Full Text] [Related]
20. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
Ariëns RA; Alberio G; Moia M; Mannucci PM
Thromb Haemost; 1999 Feb; 81(2):203-7. PubMed ID: 10063992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
